The clinical-stage company is headquartered in Cambridge, Massachusetts, and is developing next-generation treatments for depression, with a focus on patients who do not respond adequately to SSRIs. Their product, EB-1010, is expected to improve efficacy and reduce side effects associated with poor adherence to standard antidepressants, including weight gain, sexual dysfunction, and cognitive impairment. In addition to depression, Euthymics is also developing treatments for alcohol use disorder (AUD) under a collaboration with the government. According to the National Institutes of Health, over 15 million American adults suffer from major depressive disorder, while approximately 18 million Americans have AUD.